Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 10/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819797 | 0.97 | CYP3A4 (0.47) | CYP3A4ITGB3ITGA2BTSHRCYP2C9 | |
| SCHEMBL2817193 | 0.97 | CYP3A4 (0.47) | CYP3A4ITGB3ITGA2BTSHRCYP2C9 | |
| SCHEMBL2817753 | 0.96 | CYP3A4 (0.46) | CYP3A4ITGB3ITGA2BTSHRCYP2C9 | |
| SCHEMBL485183 | 0.95 | CYP3A4 (0.55) | CYP3A4ITGB3ITGA2BTSHRCYP2C9 | |
| SCHEMBL484503 | 0.91 | CYP3A4 (0.49) | CYP3A4ITGB3ITGA2BTSHRCYP2C9 | |
| SCHEMBL2817565 | 0.91 | CYP3A4 (0.53) | CYP3A4ITGB3ITGA2BTSHRCYP2C9 | |
| SCHEMBL2821881 | 0.91 | CYP3A4 (0.49) | CYP3A4ITGB3ITGA2BTSHRCYP2C9 | |
| SCHEMBL2816124 | 0.90 | CYP3A4 (0.53) | CYP3A4ITGB3ITGA2BTSHRCYP2C9 | |
| SCHEMBL484333 | 0.90 | CYP3A4 (0.49) | CYP3A4ITGB3ITGA2BTSHRCYP2C9 | |
| SCHEMBL484697 | 0.88 | CYP3A4 (0.47) | CYP3A4ITGB3ITGA2BTSHRCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | claimed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | claimed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | claimed |
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| EP-2411381-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| WO-2010108651-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | BDKRB1, BDKRB2, REN | CYP3A4 3781/4885ITGB3 3292/4885ITGA2B 3190/4885 |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | BDKRB1, BDKRB2, REN | CYP3A4 3781/4885ITGB3 3292/4885ITGA2B 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.